| 1 |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
|
| 2 |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
| 3 |
Franco EL. Persistent HPV infection and cervical cancer risk: is the scientific rationale for changing the screening paradigm enough？[J] J Natl Cancer Inst, 2010, 102(19):1451-1453.
|
| 4 |
Tjalma WA, Fiander A, Reich O, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe[J]. Int J Cancer, 2013, 132(4):854-867.
|
| 5 |
Kjær SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence[J]. J Natl Cancer Inst, 2010, 102(19):1478-1488.
|
| 6 |
Thomsen LT, Frederiksen K, Munk C, et al. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33 288 women with normal cervical cytology[J]. Int J Cancer, 2015, 137(1):193-203.
|
| 7 |
Wang R, Guo XL, Wisman GB, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China[J]. BMC Infect Dis, 2015, 15:257.
|
| 8 |
Radley D, Saah A, Stanley M. Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease[J]. Hum Vaccin Immunother, 2016, 12(3):768-772.
|
| 9 |
Trimble CL, Peng S, Thoburn C, et al. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3[J]. Cancer Immunol Immunother, 2010, 59(5):799-803.
|
| 10 |
Chang Y, Duan Y. Analysis of factors associated with recurrence of cervical intraepithelial neoplasia after loop electrosurgical excision procedure[J]. Zhonghua Yi Xue Za Zhi, 2014, 94(47):3751-3754.
|
| 11 |
Jin J, Li L, Zhang F. Meta-analysis of high risk factors of residue or relapse of cervical intraepithelial neoplasia after conization[J]. J Biol Regul Homeost Agents, 2015, 29(2):451-458.
|
| 12 |
Zivadinovic R, Lilic G, Lilic V, et al. Recurrence of cervical intraepithelial neoplasias with negative cone margins: risk factors[J]. J BUON, 2011, 16(3):498-504.
|
| 13 |
Nam K, Chung S, Kim J, et al. Factors associated with HPV persistence after conization in patients with negative margins[J]. J Gynecol Oncol, 2009, 20(2):91-95.
|
| 14 |
Ryu A, Nam K, Kwak J, et al. Early human papillomavirus testing predicts residual/recurrent disease after LEEP[J]. J Gynecol Oncol, 2012, 23(4):217-225.
|
| 15 |
缪飞，王秀丽，王宏伟，等．5-氨基酮戊酸光动力治疗宫颈高危型HPV感染[J]．中国皮肤性病学杂志，2012，26(1)：49-52.
|
| 16 |
Kim S, Buchlis G, Fridlender ZG, et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy[J]. Cancer Res, 2008, 68(24):10247-10256.
|
| 17 |
Barnard P, Payne E, McMillan NA. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha[J]. Virology, 2000, 277(2):411-419.
|
| 18 |
Zhang J, Li S, Yan Q, et al. Interferon-β induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells[J]. PLoS One, 2013, 8(12):e81366.
|
| 19 |
Chiantore MV, Mangino G, Iuliano M, et al. IFN-β antiproliferative effect and miRNA regulation in human papilloma virus E6- and E7-transformed keratinocytes[J]. Cytokine, 2015 Dec 31. pii: S1043-4666(15)30127-7. doi: 10.1016/j.cyto.2015.12.014.PMID:26748726. |
| 20 |
Choobin H, Bamdad T, Soleimanjahi H, et al. Antitumor effect of mIFN-λ3 in C57BL/6 mice model for papilloma tumors[J]. Mol Biol (Mosk), 2015, 49(5):777-784.
|
| 21 |
Stern PL, van der Burg SH, Hampson IN, et al. Therapy of human papillomavirus-related disease[J]. Vaccine, 2012, 30 (Suppl 5):F71-F82.
|
| 22 |
Grimm C, Polterauer S, Natter C, et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial[J]. Obstet Gynecol, 2012, 120(1):152-159.
|
| 23 |
Amine A, Rivera S, Opolon P, et al. Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells[J]. PLoS One, 2009, 4(3):e5018.
|
| 24 |
Snoeck R, Noel JC, Muller C, et al. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade Ⅲ (CIN Ⅲ) [J]. J Med Virol, 2000, 60(2):205-209.
|
| 25 |
陈锐，赵健，廖秦平．派特灵治疗宫颈上皮内瘤变1、2级临床疗效观察[J]．中国实用妇科与产科杂志，2011，27(9)：703-705.
|
| 26 |
宋志琴，王蔼明．派特灵治疗宫颈高危型人乳头瘤病毒感染的临床观察[J]．转化医学杂志，2015，4(5)：300-301，315.
|
| 27 |
商宇红，白丽霞，魏丽惠．中药保妇康栓对宫颈癌细胞抑制作用的分子机制研究[J]．中国妇产科临床杂志，2003，4(5)：336-338.
|
| 28 |
沈兢兢，刘志红，李鹃，等．保妇康栓和干扰素栓对低度子宫颈上皮内瘤变1级作用的临床研究[J]．中国妇产科临床杂志，2013，14(6)：509-512.
|
| 29 |
Guo X, Qiu L, Wang Y, et al. A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection [J]. Microbes Infect, 2016, 18(2):148-152.
|
| 30 |
孟亚丽，岳天孚．对子宫颈上皮内HPV持续感染的非创伤性干预的实验性研究[D]．天津：天津医科大学，2012.
|
| 31 |
Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects[J]. Drugs, 2010, 70(9):1079-1098.
|
| 32 |
乔友林，赵宇倩．宫颈癌的流行病学现状和预防[J/CD]．中华妇幼临床医学杂志：电子版，2015，11(2)：1-6.
|
| 33 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
|
| 34 |
Wang H, Yu J, Li L. A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1[J]. Onco Targets Ther, 2015, 8:3067-3077.
|
| 35 |
Vidyasagar P, Sridevi VN, Rajan S, et al. Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs[J]. Eur J Microbiol Immunol (Bp), 2014, 4(1):56-64.
|
| 36 |
Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma[J]. Cancer Res, 2013, 73(6):1733-1741.
|